Evidence map›Paper›PMID 41695340›Full record

ArticleFrontiers in oncology2026

Case Report: Re-irradiation of out-of-field recurrence of malignant phyllodes tumors of the breast after adjuvant radiotherapy.

Ziwei Li, Juan Zhong, Yingying Shi, Wenliang Lu, Yanjv Lu, Ning Ge

Abstract readCase Reports
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ziwei LiDepartment of Oncology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Juan ZhongDepartment of Oncology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yingying ShiDepartment of Oncology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wenliang LuDepartment of Thyroid and Breast Surgery, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Yanjv LuDepartment of Pathology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China.
Ning GeDepartment of Oncology, Maternal and Child Health Hospital of Hubei Province, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Phyllodes tumor of the breast (PTB) is a rare fibroepithelial neoplasm, classified as benign, borderline, and malignant. They typically present as solitary, painless, firm masses with potential rapid enlargement, and 20% exceed 10 cm, often indicating malignancy. Local recurrence frequently occurs within two years postoperatively. While the survival benefit of adjuvant radiotherapy remains controversial, it significantly reduces recurrence rates. We report a 27×14 cm malignant PTB and evaluate optimal radiotherapy strategies and re-irradiation safety in recurrent cases. Case report: A 55-year-old female presented with a rapidly enlarging left breast mass, initially detected seven years prior, measuring 50×40 cm on physical examination. The patient underwent complete surgical excision, with a postoperative pathological mass measuring 27×14 cm, followed by adjuvant radiotherapy (50 Gy/25 fractions). One month after radiation, a 15×15 cm axillary recurrence was resected (10×8 cm specimen). Two months later, a 10×8 cm infraclavicular recurrence was excised (6×5 cm specimen). Subsequently, six cycles of epirubicin-cyclophosphamide chemotherapy and re-irradiation (45-60 Gy/25 fractions) were administered. At present, there is no evidence of local recurrence. Conclusions: This case highlights the potential role of adjuvant RT in reducing recurrence and the feasibility of carefully selected re-irradiation for recurrent MPTs. Prospective studies are needed to define optimal target volume of radiotherapy, dose fractionation, and the safety of re-irradiation.

Indexed as

breast sarcomamalignant phyllodes tumorradiotherapyregional recurrencere-irradiation

Identifiers

PMID41695340
PMCPMC12893997

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.